Comparative Pharmacology
Head-to-head clinical analysis: IBUPROHM versus NALFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROHM versus NALFON.
IBUPROHM vs NALFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
None Documented
None Documented
2-4 hours in adults; prolonged to 1.5-2.5 hours in neonates? Actually: terminal half-life ~2-4 h in adults, up to 12 h in overdose; context: requires frequent dosing.
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Renal: 90% as metabolites (mostly glucuronide conjugates) and unchanged drug (1%); biliary/fecal: <5%.
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)